Raleigh Capital Management’s Medifast MED Stock Holding History

Raleigh Capital Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10	Closed	-$176	–	842
2024 Q4	$176	Buy	+10	New	+$186	﹤0.01%	997

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Raleigh Capital Management's MED Position: Q1 2025 in Review

Raleigh Capital Management sold out of Medifast (MED) in Q1 2025, closing a stake of 10 shares — an estimated $176 sold.

Raleigh Capital Management first reported a position in MED in Q4 2024 and held it in 1 quarter. The position peaked at $176 in Q4 2024. 124 funds tracked by Wall St. Rank hold MED as of Q1 2025.

Raleigh Capital Management reported no remaining Medifast position as of Q1 2025 after selling out during the quarter.
Raleigh Capital Management sold 10 Medifast shares in Q1 2025, an estimated $176.
Raleigh Capital Management first reported a position in Medifast in Q4 2024 and held it in 1 quarter.
Raleigh Capital Management's Medifast position peaked at $176 in Q4 2024.
124 funds tracked by Wall St. Rank held Medifast as of Q1 2025.

Based on Raleigh Capital Management's 13F filing for Q1 2025, filed 29 Apr 2025.